{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T01:41:53Z","timestamp":1774316513240,"version":"3.50.1"},"reference-count":135,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1016\/j.jneuroim.2010.10.020","type":"journal-article","created":{"date-parts":[[2010,11,20]],"date-time":"2010-11-20T04:24:12Z","timestamp":1290227052000},"page":"43-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Clinical and biological heterogeneity of autoimmune myasthenia gravis"],"prefix":"10.1016","volume":"231","author":[{"given":"Jozsef","family":"Pal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Csilla","family":"Rozsa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Komoly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsolt","family":"Illes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2010.10.020_bb0005","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1196\/annals.1405.040","article-title":"Myasthenia gravis in the elderly: is it different?","volume":"1132","author":"Aarli","year":"2008","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0010","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11940-005-0022-2","article-title":"An update on myasthenic crisis","volume":"7","author":"Ahmed","year":"2005","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0015","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.4049\/jimmunol.180.4.2132","article-title":"Ex vivo generated regulatory T cells modulate experimental autoimmune myasthenia gravis","volume":"180","author":"Aricha","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0020","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2003-11-3900","article-title":"Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis","volume":"105","author":"Balandina","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0025","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1084\/jem.186.3.385","article-title":"Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice","volume":"186","author":"Balasa","year":"1997","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0030","doi-asserted-by":"crossref","first-page":"10638","DOI":"10.1073\/pnas.90.22.10638","article-title":"Identification of a hexapeptide that mimics a conformation-dependent binding site of acetylcholine receptor by use of a phage-epitope library","volume":"90","author":"Balass","year":"1993","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0035","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1212\/01.wnl.0000228225.23349.5d","article-title":"Anti-MuSK antibodies: correlation with myasthenia gravis severity","volume":"67","author":"Bartoccioni","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0040","first-page":"CD005081","article-title":"Medical and surgical treatment for ocular myasthenia","volume":"2","author":"Benatar","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0045","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1212\/01.wnl.0000263481.14289.90","article-title":"Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"68","author":"Benatar","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0050","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0002-9440(10)62960-4","article-title":"Increased toll-like receptor 4 expression in thymus of myasthenic patients with thymitis and thymic involution","volume":"167","author":"Bernasconi","year":"2005","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0055","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1097\/00003246-199707000-00027","article-title":"Therapy of myasthenic crisis","volume":"25","author":"Berrouschot","year":"1997","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0060","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1212\/01.wnl.0000327669.75695.38","article-title":"Treatment of ocular symptoms in myasthenia gravis","volume":"71","author":"Bhanushali","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0065","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/mus.20075","article-title":"Corticosteroid use in the treatment of neuromuscular disorders: empirical and evidence-based data","volume":"30","author":"Bromberg","year":"2003","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0070","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1212\/WNL.0b013e3181d7d884","article-title":"Detection of poliovirus-infected macrophages in thymus of patients with myasthenia gravis","volume":"74","author":"Cavalcante","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0075","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/ana.21902","article-title":"Epstein\u2013Barr virus persistence and reactivation in myasthenia gravis thymus","volume":"67","author":"Cavalcante","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0080","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00415-008-0718-9","article-title":"Mycophenolate mofetil for ocular myasthenia","volume":"255","author":"Chan","year":"2008","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0085","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/ana.20577","article-title":"A CTLA4high genotype is associated with myasthenia gravis in thymoma patients","volume":"58","author":"Chuang","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0090","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/gene.2009.64","article-title":"The PTPN22gain-of-function+1858T(+) genotypes correlate with low IL-2 expression in thymomas and predispose to myasthenia gravis","volume":"10","author":"Chuang","year":"2009","journal-title":"Genes Immun."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0095","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/ana.21371","article-title":"Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction","volume":"63","author":"Cole","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0100","doi-asserted-by":"crossref","DOI":"10.1113\/jphysiol.2010.190298","article-title":"Patient autoantibodies deplete postsynaptic muscle specific kinase leading to disassembly of the ACh receptor scaffold and myasthenia gravis in mice","author":"Cole","year":"2010","journal-title":"J. Physiol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0105","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1196\/annals.1405.042","article-title":"CD4+ T cells and cytokines in the pathogenesis of acquired myasthenia gravis","volume":"1132","author":"Conti-Fine","year":"2008","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0110","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1600-0404.1991.tb04899.x","article-title":"Effectiveness of steroid treatment in myasthenia gravis: a retrospective study","volume":"84","author":"Cosi","year":"1991","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0115","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mus.10133","article-title":"Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis","volume":"26","author":"De Feo","year":"2002","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0120","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1212\/01.wnl.0000254620.45529.97","article-title":"Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis","volume":"68","author":"Deymeer","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0125","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ana.10400","article-title":"Treatment of refractory myasthenia: \u201crebooting\u201d with high-dose cyclophosphamide","volume":"53","author":"Drachman","year":"2003","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0130","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2008.02246.x","article-title":"EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases","volume":"15","author":"Elovaara","year":"2008","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0135","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000116785","article-title":"Long-term results of corticosteroid therapy in patients with myasthenia gravis","volume":"32","author":"Evoli","year":"1992","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0140","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/brain\/awg223","article-title":"Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis","volume":"126","author":"Evoli","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0145","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1196\/annals.1405.012","article-title":"Response to therapy in myasthenia gravis with anti-MuSK antibodies","volume":"1132","author":"Evoli","year":"2008","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0150","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/mus.21280","article-title":"Myasthenia gravis associated with etanercept therapy","volume":"39","author":"Fee","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0155","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1586\/14737175.8.6.979","article-title":"Myasthenia gravis during pregnancy","volume":"8","author":"Ferrero","year":"2008","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0160","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group","volume":"41","author":"Gajdos","year":"1997","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0165","first-page":"CD002277","article-title":"Intravenous immunoglobulin for myasthenia gravis","volume":"23","author":"Gajdos","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0170","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1212\/WNL.57.9.1555","article-title":"Linkage of HLA to myasthenia gravis and genetic hetero: geneity depending on anti-titin antibodies","volume":"57","author":"Giraud","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0175","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/sj.gene.6364041","article-title":"Association of the gene encoding the delta-subunit of the muscle acetylcholine receptor (CHRND) with acquired autoimmune myasthenia gravis","volume":"5","author":"Giraud","year":"2004","journal-title":"Genes Immun."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0180","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/nature06066","article-title":"An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus","volume":"448","author":"Giraud","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0185","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1196\/annals.1405.027","article-title":"Genetic factors in autoimmune myasthenia gravis","volume":"1132","author":"Giraud","year":"2008","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0190","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0165-5728(01)00474-X","article-title":"Tumor necrosis factor receptor p55 and p75 deficiency protects mice from developing experimental autoimmune myasthenia gravis","volume":"122","author":"Goluszko","year":"2002","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0195","doi-asserted-by":"crossref","DOI":"10.3109\/08916930903555943","article-title":"Antibody effector mechanisms in myasthenia gravis\u2014pathogenesis at the neuromuscular junction","author":"Gomez","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0200","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.humimm.2009.04.027","article-title":"The autoimmunity-related polymorphism PTPN22 1858C\/T is associated with anti-titin antibody-positive myasthenia gravis","volume":"70","author":"Greve","year":"2009","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0205","series-title":"Myasthenia Gravis and Myasthenic Disorders","first-page":"135","article-title":"Natural history of myasthenia gravis","author":"Grob","year":"1999"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0210","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1212\/WNL.55.1.7","article-title":"Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"55","author":"Gronseth","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0215","doi-asserted-by":"crossref","DOI":"10.1097\/WCO.0b013e32833c0982","article-title":"Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis","author":"Guptill","year":"2010","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0220","first-page":"CD005224","article-title":"Immunosuppressive agents for myasthenia gravis","volume":"17","author":"Hart","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0225","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/jnnp.2008.144980","article-title":"Immunosuppressant drugs for myasthenia gravis","volume":"80","author":"Hart","year":"2009","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/gene.2009.61","article-title":"A functional SNP in the regulatory region of the decay-accelerating factor gene associates with extraocular muscle pareses in myasthenia gravis","volume":"11","author":"Heckmann","year":"2010","journal-title":"Genes Immun."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0235","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/mus.21640","article-title":"Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients","volume":"41","author":"Hehir","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0240","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis, without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0245","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1749-6632.1987.tb51321.x","article-title":"Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis","volume":"505","author":"Howard","year":"1987","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0250","doi-asserted-by":"crossref","unstructured":"Illa I., Diaz-Manera J., Rojas-Garcia R., Pradas J., Rey A., Blesa R., Juarez C., Gallardo E. 2008. Sustained response to Rituximab in anti-AchR and anti-MuSK positive myasthenia gravis patients. J Neuroimmunol 201\u2013202, 90\u201394.","DOI":"10.1016\/j.jneuroim.2008.04.039"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0255","doi-asserted-by":"crossref","first-page":"18680","DOI":"10.1073\/pnas.0909307106","article-title":"Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases","volume":"106","author":"IMAGEN","year":"2009","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0260","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jns.2007.04.045","article-title":"Myasthenic crisis: guidelines for prevention and treatment","volume":"261","author":"Jani-Acsadi","year":"2007","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0265","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0270","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jneuroim.2006.03.016","article-title":"Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK)","volume":"175","author":"Jha","year":"2006","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0275","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1111\/j.1742-4658.2007.05935.x","article-title":"Muscle and neuronal nicotinic acetylcholine receptors: structure, function and pathogenecity","volume":"274","author":"Kalamida","year":"2007","journal-title":"FEBS J."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0280","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.expneurol.2004.06.005","article-title":"Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis","volume":"189","author":"Kaminski","year":"2004","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0285","doi-asserted-by":"crossref","first-page":"5236","DOI":"10.4049\/jimmunol.164.10.5236","article-title":"Absence of IFN-gamma or IL-12 has different effects on experimental myasthenia gravis in C57BL\/6 mice","volume":"164","author":"Karachunski","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0290","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.4049\/jimmunol.152.6.3152","article-title":"Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis","volume":"152","author":"Kaul","year":"1994","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0295","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1007\/s00415-009-5120-8","article-title":"Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up","volume":"256","author":"Kupersmith","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0300","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/archneur.60.2.243","article-title":"Development of generalized disease at 2years in patients with ocular myasthenia gravis","volume":"60","author":"Kupersmith","year":"2003","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0305","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1212\/01.WNL.0000150587.71497.B6","article-title":"Thymus changes in anti-MuSK-positive and -negative myasthenia gravis","volume":"64","author":"Lauriola","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0310","doi-asserted-by":"crossref","DOI":"10.3109\/08916930903563491","article-title":"Thymic remodeling associated with hyperplasia in myasthenia gravis","author":"Le Panse","year":"2010","journal-title":"Autoimmunity"},{"issue":"3","key":"10.1016\/j.jneuroim.2010.10.020_bb0315","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.20386","article-title":"Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG","volume":"57","author":"Leite","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0320","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in \u201cseronegative\u201d myasthenia gravis","volume":"131","author":"Leite","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/08916930903541208","article-title":"Diagnostic use of autoantibodies in myasthenia gravis","volume":"43","author":"Leite","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0330","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","article-title":"Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value","volume":"26","author":"Lindstrom","year":"1976","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0335","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1196\/annals.1405.007","article-title":"Myasthenia gravis and the tops and bottoms of AchRs","volume":"1132","author":"Linsdtrom","year":"2008","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0340","doi-asserted-by":"crossref","first-page":"7898","DOI":"10.4049\/jimmunol.175.12.7898","article-title":"Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia","volume":"175","author":"Liu","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0345","doi-asserted-by":"crossref","first-page":"13898","DOI":"10.1523\/JNEUROSCI.2833-09.2009","article-title":"Main immunogenic region structure promotes binding of conformation-dependent myasthenia gravis autoantibodies, nicotinic acetylcholine receptor conformation maturation, and agonist sensitivity","volume":"29","author":"Luo","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0350","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jneuroim.2005.03.011","article-title":"Decreased frequency of intrathymic regulatory T cells in patients with myasthenia-associated thymoma","volume":"164","author":"Luther","year":"2005","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0355","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jneuroim.2008.06.016","article-title":"Preferential expression of AChR epsilon-subunit in thymomas from patients with myasthenia gravis","volume":"201\u2013202","author":"Maclennan","year":"2008","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0360","article-title":"The use of rituximab in myasthenia gravis and Lambert\u2013Eaton myasthenic syndrome","author":"Maddison","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0365","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.athoracsur.2009.08.074","article-title":"Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery","volume":"89","author":"Margaritora","year":"2010","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0370","doi-asserted-by":"crossref","DOI":"10.3109\/08916930903555935","article-title":"Thymoma and paraneoplastic myasthenia gravis","author":"Marx","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0375","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1093\/hmg\/ddq110","article-title":"Mutations in MUSK causing congenital myasthenic syndrome impair MuSK\u2013Dok-7 interaction","volume":"19","author":"Maselli","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0380","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1212\/WNL.0b013e3181d31e47","article-title":"Undiminished regulatory T cells in the thymus of patients with myasthenia gravis","volume":"74","author":"Matsui","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0385","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cccn.2004.05.008","article-title":"Muscle-specific receptor tyrosine kinase autoantibodies \u2014 a new immunoprecipitation assay","volume":"348","author":"Matthews","year":"2004","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0390","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ana.20061","article-title":"Detection and characterization of MuSK antibodies in seronegative myasthenia gravis","volume":"55","author":"McConville","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0395","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1046\/j.1365-2249.2003.02113.x","article-title":"Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing antibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and\/or myasthenia gravis","volume":"132","author":"Meager","year":"2003","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0400","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0405","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1212\/01.WNL.0000094122.88929.0B","article-title":"Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability","volume":"61","author":"Meriggioli","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0410","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1172\/JCI117050","article-title":"Epitopes on the beta subunit of human muscle acetylcholine receptor recognized by CD4+ cells of myasthenia gravis patients and healthy subjects","volume":"93","author":"Moiola","year":"1994","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0415","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000085833","article-title":"Efficacy of low-dose FK506 in the treatment of myasthenia gravis\u2014a randomized pilot study","volume":"53","author":"Nagane","year":"2005","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0420","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1212\/WNL.40.4.581","article-title":"Immune studies in human immunodeficiency virus infection with myasthenia gravis: a case report","volume":"40","author":"Nath","year":"1990","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0425","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1212\/01.wnl.0000218159.79769.5c","article-title":"Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5","volume":"66","author":"Niks","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0430","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3988\/jcn.2009.5.2.53","article-title":"Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status","volume":"5","author":"Oh","year":"2009","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0435","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1468-1331.1998.520137.x","article-title":"The management and outcome of patients with myasthenia gravis treated acutely in a neurological intensive care unit","volume":"5","author":"O'Riordan","year":"1998","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0440","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0445","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ana.410150316","article-title":"Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients","volume":"15","author":"Pascuzzi","year":"1984","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0450","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/mus.21533","article-title":"Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience","volume":"41","author":"Pasnoor","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0455","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.4049\/jimmunol.174.10.5941","article-title":"Effects of cytokines on acetylcholine receptor expression: implications for myasthenia gravis","volume":"174","author":"Po\u00eba-Guyon","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0460","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1196\/annals.1405.000","article-title":"Tacrolimus for myasthenia gravis: a clinical study of 212 patients","volume":"1132","author":"Ponseti","year":"2008","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0465","doi-asserted-by":"crossref","first-page":"12062","DOI":"10.1073\/pnas.211257298","article-title":"Extraocular muscle is defined by a fundamentally distinct gene expression profile","volume":"98","author":"Porter","year":"2001","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0470","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1046\/j.1468-1331.2003.00678.x","article-title":"Disease severity and outcome in thymoma myasthenia gravis: a long-term observation study","volume":"10","author":"Romi","year":"2003","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0475","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1468-1331.2005.01137.x","article-title":"Seronegative myasthenia gravis: disease severity and prognosis","volume":"12","author":"Romi","year":"2005","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0480","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1468-1331.2007.01785.x","article-title":"Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features","volume":"14","author":"Romi","year":"2007","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0485","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1212\/01.WNL.0000147242.92691.71","article-title":"Etanercept treatment in corticosteroid-dependent myasthenia gravis","volume":"63","author":"Rowin","year":"2004","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jneuroim.2010.10.020_bb0490","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/j.1468-1331.2006.01382.x","article-title":"Safety of long-term combined immunosuppressive treatment in myasthenia gravis\u2014analysis of adverse effects of 163 patients","volume":"13","author":"Rozsa","year":"2006","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0495","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/j.1468-1331.2009.02634.x","article-title":"Long-term effects of combined immunosuppressive treatment on myasthenic crisis","volume":"16","author":"R\u00f3zsa","year":"2009","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0500","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3109\/08916930903518107","article-title":"Immunosuppressive therapies in myasthenia gravis","volume":"43","author":"Sanders","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0505","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0510","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1196\/annals.1405.031","article-title":"Lessons from two trials of mycophenolate mofetil in myasthenia gravis","volume":"1132","author":"Sanders","year":"2008","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0515","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1212\/01.WNL.0000065882.63904.53","article-title":"Clinical aspects of MuSK antibody positive seronegative MG","volume":"60","author":"Sanders","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0520","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0525","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1212\/WNL.34.2.170","article-title":"Myasthenia gravis: prolonged treatment with steroids","volume":"34","author":"Sghirlanzoni","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0530","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1212\/WNL.38.9.1417","article-title":"Canine and human myasthenia gravis autoantibodies recognize similar regions on the acetylcholine receptors","volume":"38","author":"Shelton","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0535","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1172\/JCI21545","article-title":"Induction of myasthenia by immunization against muscle-specific kinase","volume":"116","author":"Shigemoto","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0540","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1196\/annals.1254.026","article-title":"Scenarios for autoimmunization of T and B cells in myasthenia gravis","volume":"998","author":"Shiono","year":"2003","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0545","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1468-1331.2008.02242.x","article-title":"Paraneoplastic myasthenia gravis: immunological and clinical aspects","volume":"15","author":"Skeie","year":"2008","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0550","doi-asserted-by":"crossref","DOI":"10.1111\/j.1468-1331.2010.03019.x","article-title":"Guidelines for treatment of autoimmune neuromuscular transmission disorders","author":"Skeie","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0555","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/jnnp.62.2.156","article-title":"Ocular myasthenia gravis: response to long-term immunosuppressive treatment","volume":"62","author":"Sommer","year":"1997","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0560","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1196\/annals.1405.004","article-title":"Thymectomy for nonthymomatous myasthenia gravis: a critical analysis","volume":"1132","author":"Sonett","year":"2008","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0565","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1200\/JCO.2004.10.113","article-title":"Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis","volume":"22","author":"Str\u00f6bel","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0570","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/ana.20340","article-title":"Selective loss of regulatory T cells in thymomas","volume":"56","author":"Str\u00f6bel","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0575","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.clim.2004.04.005","article-title":"Increase of circulating CD4+CD25+ T cells in myasthenia gravis patients with stability and thymectomy","volume":"112","author":"Sun","year":"2004","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0580","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/eji.200636962","article-title":"Highly variable expression of tissue-restricted self-antigens in human thymus: implications for self-tolerance and autoimmunity","volume":"37","author":"Taubert","year":"2007","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0585","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.2353\/ajpath.2009.090040","article-title":"The effect of plasma from muscle-specific tyrosine kinase myasthenia patients on regenerating endplates","volume":"175","author":"ter Beek","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0590","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM198703193161205","article-title":"Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis","volume":"316","author":"Tindall","year":"1987","journal-title":"N Engl J. Med."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0595","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1749-6632.1993.tb22937.x","article-title":"A clinical therapeutic trial of cyclosporine in myasthenia gravis","volume":"681","author":"Tindall","year":"1993","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0600","doi-asserted-by":"crossref","first-page":"15464","DOI":"10.1073\/pnas.0406756101","article-title":"Pleiotropic effects of the 8.1 HLA haplotype in patients with autoimmune myasthenia gravis and thymus hyperplasia","volume":"101","author":"Vandiedonck","year":"2004","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0605","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/ana.20751","article-title":"Association of the PTPN22*R620W polymorphism with autoimmune myasthenia gravis","volume":"59","author":"Vandiedonck","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0610","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jneuroim.2009.02.004","article-title":"Association of HLA-A in autoimmune myasthenia gravis with thymoma","volume":"210","author":"Vandiedonck","year":"2009","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0615","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.it.2006.06.001","article-title":"TGFbeta1, a \u201cJack of all trades\u201d: the link with pro-inflammatory IL-17-producing T cells","volume":"27","author":"Veldhoen","year":"2006","journal-title":"Trends Immunol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0620","doi-asserted-by":"crossref","DOI":"10.3109\/08916931003602130","article-title":"Clinical aspects of myasthenia explained","author":"Verschuuren","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0625","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1136\/jnnp.74.8.1105","article-title":"Evidence of underdiagnosis of myasthenia gravis in older people","volume":"74","author":"Vincent","year":"2003","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0630","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1196\/annals.1405.020","article-title":"Myasthenia gravis seronegative for acetylcholine receptor antibodies","volume":"1132","author":"Vincent","year":"2008","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0635","doi-asserted-by":"crossref","DOI":"10.3109\/08916930903518073","article-title":"The auto-antigen repertoire in myasthenia gravis","author":"Vrolix","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0640","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/sj.gene.6363816","article-title":"CDS1 and promoter single nucleotide polymorphisms of the CTLA-4 gene in human myasthenia gravis","volume":"3","author":"Wang","year":"2002","journal-title":"Genes Immun."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0645","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4049\/jimmunol.172.1.97","article-title":"The susceptibility to experimental myasthenia gravis of STAT6\u2212\/\u2212 and STAT4\u2212\/\u2212 BALB\/c mice suggests a pathogenic role of Th1 cells","volume":"172","author":"Wang","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0650","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1196\/annals.1405.021","article-title":"Autoimmunizing mechanisms in thymoma and thymus","volume":"1132","author":"Willcox","year":"2008","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0655","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1196\/annals.1405.005","article-title":"Clinical phenotype of muscle-specific tyrosine kinase-antibody-positive myasthenia gravis","volume":"1132","author":"Wolfe","year":"2008","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0660","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0165-5728(94)90044-2","article-title":"Acetylcholine receptor-reactive T cells in myasthenia gravis: evidence for the involvement of different subpopulations of T helper cells","volume":"50","author":"Yi","year":"1994","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0665","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.nmd.2004.10.002","article-title":"Extraocular muscles have fundamentally distinct properties that make them selectively vulnerable to certain disorders","volume":"15","author":"Yu Wai Man","year":"2005","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0670","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/mus.21521","article-title":"Rituximab in the management of refractory myasthenia gravis","volume":"41","author":"Zebardast","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2010.10.020_bb0675","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.4049\/jimmunol.162.7.3775","article-title":"Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis","volume":"162","author":"Zhang","year":"1999","journal-title":"J. Immunol."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572810004704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572810004704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:14:50Z","timestamp":1759047290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572810004704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":135,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["S0165572810004704"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2010.10.020","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and biological heterogeneity of autoimmune myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2010.10.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}